Vaccine focus Private biotech with active vaccine R&D across multiple pathogens including West Nile, Tick-borne flaviviruses, Zika, Crimean-Congo hemorrhagic fever, and Chikungunya; potential partnerships around vaccine development, adjuvants, and preclinical/clinical collaborations.

Biodefense specialty Diversified pipeline includes anti-toxin small molecules targeting bacterial toxins (anthrax lethal factor, botulinum toxin) and a proprietary saponin adjuvant; selling points for government or defense-related contracts and biosurveillance collaborations.

Growth potential Moderate revenue scale with estimated 10–25 million and around 12 million in funding; room for expansion through late-stage vaccine partnerships, licensing deals, and contract development/manufacturing opportunities.

Recent leadership transition Past leadership change with CEO retirement in 2021; leverage continuity plans and potential re-scoping of partnerships or funding rounds to align with new strategic directions.

Technology & ecosystem Tech stack and platform focus on recombinant protein production, vaccine development, and adjuvant technology; opportunities to integrate with contract manufacturing, regulatory consulting, or joint development arrangements with larger pharma players.